The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And big juicy new team Inc new CEO
I’m not doing anything Tils are!
With the approval of the fda the way they wanted it done.
A bit sad that you think you can achieve anything with a compassionate use program rather than running a clinical trial.
sang is a desperate ramper for 4d and likes to d ramp any other bio they perceive as a threat to their investment choice.... a bit sad really .
there are now two patients now being treated with fmab for MS ....a second was added in January .
AccuStem gets a new trading symbol. $ACUT - on the road towards Nasdaq.
Yanks running this up in case they lose their Shorting cash cow from Nasdaq?
looking better, up nearly 50% in 5 days, have we dare I say it seen the bottom here?
Then more and more patients .
Sangi …… 2 patients!!!
There is no MS trial Paul.
It's a compassionate use program in 1 patient.
It will produce an anecdote.
Trials need to be run in multiple patients.
Otherwise are you suggesting all other biotechs are doing it wrong?
MS trial is going to the next due lift.
Or could be the $5 buy back first.
The rest of the information due from the company is trial starts or something left field that's not been published or due.
Anyone have any idea, guess or gut feeling of which of Tils Novel Immunotherapies is going to produce the goods to lift the share price significantly? It all looks quite early stage to me. Anything potentially left field?
Thks for your posts @Bluebelly btw.
So,hopefully..by 22nd Aug we'll have been sailing over the $1 compliance threshold for 10 consecutive days..woohooooo!
Seriously tho..just have to do what we've all become accustemed to at this stage....wait.
From SEC filing:
'On February 22, 2022, Tiziana Life Sciences Ltd. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department
(the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the
Company’s common shares had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq
Stock Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”).
The Notice has no immediate effect on the listing of the Company’s common shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the
Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the
closing bid price of the Company’s common shares must be at least $1.00 per share for a minimum of 10 consecutive trading days during this 180-day
compliance period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(G). The compliance period for
the Company will expire on August 22, 2022.
In the event that the Company does not regain compliance within the 180-day compliance period, the Company may be eligible for an additional 180
calendar day compliance period. To qualify, the Company would need to meet the continued listing requirement for market value of publicly held shares
and all other initial listing standards for Nasdaq, with the exception of the Minimum Bid Requirement, and provide written notice to the Staff of its
intention to cure the deficiency during the second compliance period. However, if it appears to the Staff that the Company will not be able to cure the
deficiency, or if the Company does not meet the other listing standards, the Staff could provide notice that the Company’s common shares will become
subject to delisting. In the event the Company receives notice that its common shares is being delisted, the Nasdaq Listing Rules permit the Company to
appeal any such delisting determination by the Staff to a Hearings Panel.
The Company intends to actively monitor the closing bid price of its common shares and is evaluating available options to regain compliance with the
Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or that the
Company will otherwise remain in compliance with the other listing standards for the Nasdaq Stock Market'
BB
re dangers of low sp and delist
When it suits the BOD's, Accustem had nothing to do with Tiziana Life Sciences anymore. This was stated to knock back shareholders from asking pressing questions. However, if it's a positive publication, lets push the information out there.
Let's see if the rise can be held onto. Highest close since the 10th Feb.
BB
Somebody should tell the devil to put a coat on , hell may be about to freeze over ????
yep offical rns
Thanks
is that an official RNS, or just a press release? still cant do anything with my shares on HL!
The research is now on the AccuStem website.
http://www.accustem.com/assets/accustem-stemprinter-demonstrates-prognostic-utility-01mar22.pdf
http://www.accustem.com/assets/accustem-stemprinter-demonstrates-prognostic-utility-01mar22.pdf
any link to that please?
first RNS on accustem this morning! looks good news